[The cost of type 2 diabetes in Spain: the CODE-2 study]
- PMID: 12459134
- DOI: 10.1016/s0213-9111(02)71973-0
[The cost of type 2 diabetes in Spain: the CODE-2 study]
Abstract
Objective: To estimate the cost of providing health care to patients with type 2 diabetes, by differentiating costs of the disease, costs of complications, and other unrelated health costs.
Methods: Data on resource use were retrospectively collected from medical records and personal interviews in 29 primary health care centers in Spain. Patients were randomly selected from each center's diabetes registry.
Results: We evaluated 1004 patients (561 women) with a mean age of 67.42 years and a mean disease duration of 10.07 years. A total of 50.9% had no complications, 17.7% had macrovascular complications only, 19.5% had microvascular complications only and 11.9% presented both types of complication. The annual health cost per patient was 1305.15 euros. Of this cost, 28.6% (373.27 euros) was directly related to diabetes control, 30.51% (398.20 euros) was related to complications of the disease, and 40.89% (533.68 euros) was unrelated. The mean cost of patients with no complications was 883 euros compared with 1403 euros for those with microvascular complications, 2022 euros for those with macrovascular complications and 2133 euros for patients with both types of complication.
Conclusions: Because of the high cost of treating type 2 diabetes and its complications, preventive measures should be implemented and control of the disease should be improved to reduce the costs associated with chronic complications.
Similar articles
-
The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system.Value Health. 2011 Jul-Aug;14(5 Suppl 1):S137-40. doi: 10.1016/j.jval.2011.05.009. Value Health. 2011. PMID: 21839888
-
The cost of treating type 2 diabetes (CODEIRE).Ir Med J. 2006 Nov-Dec;99(10):307-10. Ir Med J. 2006. PMID: 17274175
-
Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain.Eur J Health Econ. 2016 Nov;17(8):1001-1010. doi: 10.1007/s10198-015-0742-5. Epub 2015 Nov 5. Eur J Health Econ. 2016. PMID: 26542160 Free PMC article.
-
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.Pharmacoeconomics. 2006;24 Suppl 1:49-59. doi: 10.2165/00019053-200624001-00005. Pharmacoeconomics. 2006. PMID: 16800162 Review.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
-
The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years.J Clin Med. 2015 May 28;4(6):1207-16. doi: 10.3390/jcm4061207. J Clin Med. 2015. PMID: 26239554 Free PMC article. Review.
-
Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain).Diabetes Care. 2012 Apr;35(4):774-9. doi: 10.2337/dc11-1679. Epub 2012 Feb 16. Diabetes Care. 2012. PMID: 22344609 Free PMC article.
-
[Effect of type-2 diabetes mellitus on the quality of life of patients treated at primary care consultations in Spain].Aten Primaria. 2003 May 15;31(8):493-9. doi: 10.1016/s0212-6567(03)70722-7. Aten Primaria. 2003. PMID: 12765587 Free PMC article. Spanish.
-
Cost-utility analysis of gastric bypass for severely obese patients in Spain.Obes Surg. 2014 Dec;24(12):2061-8. doi: 10.1007/s11695-014-1304-0. Obes Surg. 2014. PMID: 24913241
-
Development and Validation of a Discrete Event Simulation Model to Evaluate the Cardiovascular Impact of Population Policies for Obesity.Med Decis Making. 2022 Feb;42(2):241-254. doi: 10.1177/0272989X211032964. Epub 2021 Oct 11. Med Decis Making. 2022. PMID: 34632840 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical